Bristol-Myers Sues XSpray to Block Copies of Blockbuster Sprycel

Bristol-Myers Squibb Co. filed a lawsuit alleging XSpray Pharma AB’s proposed branded generic version of Sprycel tablets infringes two patents for the blockbuster leukemia drug, which generated more revenue last year than all but five of Bristol-Myers’ products.

XSpray, based in Solna, Sweden, wants to sell a cheaper copy of Sprycel’s 100-milligram tablets, according to a complaint filed Wednesday in the U.S. District Court for the District of New Jersey. Bristol-Myers is seeking court orders blocking approval by the U.S. Food and Drug Administration of XSpray’s branded copycat, called Dasynoc, and blocking XSpray from making it until the patents ...